Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

112.49
-1.6000-1.40%
Post-market: 112.870.3800+0.34%19:52 EDT
Volume:7.26M
Turnover:818.28M
Market Cap:139.58B
PE:22.45
High:114.05
Open:113.45
Low:112.15
Close:114.09
52wk High:121.83
52wk Low:81.83
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.96
T/O Rate:0.59%
Dividend:3.12
Dividend Rate:2.77%
EPS(TTM):5.01
EPS(LYR):0.3849
ROE:33.40%
ROA:12.62%
PB:7.09
PE(LYR):292.24

Loading ...

Gilead Sciences: European Commission Authorizes Twice-Yearly Yeytuo (Lenacapavir) for Hiv Prevention

THOMSON REUTERS
·
Aug 26

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

Benzinga_recent_news
·
Aug 26

Suze Orman reveals her favorite stock right now and the investing mistake that shaped her strategy

Dow Jones
·
Aug 24

Suze Orman is known for money advice - now she's sharing her stock picks and biggest investing mistake

Dow Jones
·
Aug 22

Gilead's Kite to Acquire Interius BioTherapeutics for $350 Million to Boost In Vivo CAR Therapeutics

Reuters
·
Aug 21

Kite: Transaction With Interius Is Expected to Reduce Gilead's Gaap and Non-Gaap 2025 EPS by Approximately $0.23-$0.25

THOMSON REUTERS
·
Aug 21

Kite to Acquire Interius Biotherapeutics to Advance in Vivo Platform

THOMSON REUTERS
·
Aug 21

Kite: Proposed Deal for $350 Mln.

THOMSON REUTERS
·
Aug 21

Shares of Gilead Down 2.9% Premarket After Reuters Report CVS Holds off Adding Co's New Hiv Prevention Shot to Drug Coverage Lists

THOMSON REUTERS
·
Aug 21

EXCLUSIVE-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

Reuters
·
Aug 21

Exclusive - CVS Health Not yet Adding Gilead Sciences' New Hiv Prevention Injection Yeztugo to Its Commercial or Aca Plans

THOMSON REUTERS
·
Aug 21

Gilead Sciences Inc. to Present at Cantor Global Healthcare Conference

Reuters
·
Aug 21

Bernstein Adjusts Price Target on Gilead Sciences to $135 From $120, Maintains Outperform Rating

MT Newswires Live
·
Aug 20

Walgreens Specialty Pharmacy Expands Limited Distribution Network

MT Newswires Live
·
Aug 19

Gilead Sciences Inc. CFO Andrew D. Dickinson Reports Disposal of Common Shares

Reuters
·
Aug 19

Mizuho Adjusts Price Target on Gilead Sciences to $131 From $117, Maintains Outperform Rating

MT Newswires Live
·
Aug 18

Gilead Sciences Inc. Appoints Erin Burkhart as Senior Vice President and Principal Accounting Officer

Reuters
·
Aug 15

BRIEF-Mubadala Reports Stake in Disney and Merck, Dissolves Stake in Comcast

Reuters
·
Aug 14

Mubadala Investment Co Pjsc Dissolves Share Stake in Nordstrom

THOMSON REUTERS
·
Aug 14

Xilio Therapeutics Reports Q2 2025 Results: Collaboration and License Revenue Surges to $8.1M; Net Loss Widens to $15.8M

Reuters
·
Aug 14